Parecoxib, a well‐recognized nonsteroidal anti‐inflammatory drug, has been reported to
possess anticancer properties in various tumor types. In this work, we aimed to investigate …

Background Parecoxib plays an important role in inhibition of human cancer. However, the
effect of parecoxib on esophageal squamous cell carcinoma (ESCC) is still not well known …

Although the efficacy of celecoxib on various cancer cell behaviors, including aberrant
proliferation, in cultured hepatocellular carcinoma (HCC) cells has been demonstrated …

Abstract Purpose: Cyclooxygenase-2 (COX-2) inhibitors cause growth inhibition of human
hepatocellular carcinoma cells but it remains unclear whether this is both COX-2 dependent …

Chronic inflammation has long been associated to carcinogenesis. Evidence has shown that
nonsteroidal anti-inflammatory drugs (NSAIDs) may decrease the risk of certain types of …

Celecoxib, a COX-2 inhibitor and non-steroidal anti-inflammatory drug, can prevent several
types of cancer, including hepatocellular carcinoma (HCC). Here we show that celecoxib …

Previous studies have demonstrated that the selective cyclooxygenase‐2 (COX‐2) inhibitor
celecoxib shows efficacy against multiple cancers, including hepatocellular carcinoma …

Colorectal cancer is the third leading cause of cancer death in Taiwan. Current treatments
involve combination of surgical resection, radiation, and chemotherapy. These treatments …

Celecoxib Inhibits Hepatocellular Carcinoma Cell Growth and Migration by Targeting PNO1 -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Different types of tumors often present an overexpression of cyclooxygenase-2. The aim of
this study was to evaluate the effects of parecoxib (NSAID, cyclooxygenase-2 selective …